Backed by a $16M investment, this collaborative effort will help define the next generation of combination therapy strategies for pancreatic cancer

在1600万美元投资的的支持下，这项合作将有助于定义胰腺癌联合治疗策略的下一代方案。

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

June 29, 2026

2026年6月29日

/PRNewswire/ -- At a pivotal moment for pancreatic cancer, Break

/美通社/ -- 在胰腺癌治疗的关键时刻，Break

Through

通过

Cancer and the Lustgarten Foundation today, with support from the Cinelli Family Foundation, announced a $16 million investment in the

癌症与卢斯特加滕基金会今日在奇内利家族基金会的支持下，宣布了一项1600万美元的投资，用于

Conquering KRAS for Patients with Pancreatic Cancer TeamLab

为胰腺癌患者攻克KRAS：TeamLab

.

。

Spanning six world-class cancer research institutions, this initiative aims to improve outcomes for one of the deadliest cancers by focusing on KRAS, a gene that is mutated in more than 90% of pancreatic cancer cases.

该倡议联合六家世界一流癌症研究机构，旨在通过聚焦于在超过90%的胰腺癌病例中发生突变的KRAS基因，改善这种最致命癌症之一的治疗结局。

Continue Reading

继续阅读

New initiative builds on one of the most deeply profiled pancreatic cancer studies to accelerate future therapies.

新举措基于一项剖析最为深入的胰腺癌研究，以加速未来疗法的开发。

Post this

发布此内容

Break Through Cancer and the Lustgarten Foundation, with support from the Cinelli Family Foundation, are partnering to accelerate the next generation of pancreatic cancer therapies.

在奇内利家族基金会的支持下，“突破癌症”组织与拉斯加滕基金会正在合作，以加速下一代胰腺癌疗法的研发。

The initiative comes amid a sea of change in the field. After decades in which oncogenic RAS proteins were considered 'undruggable' a new generation of RAS-directed therapies is showing promise and delivering encouraging results for patients with pancreatic cancer. Yet, while these advances offer invaluable hope for patients and their families, important questions remain about how pancreatic tumors respond to RAS-directed therapy and how future treatment strategies may achieve more durable benefit.

在这一领域经历巨大变革的背景下，该倡议应运而生。在致癌性RAS蛋白被视为“不可成药”的数十年之后，新一代靶向RAS疗法正展现出前景，并为胰腺癌患者带来令人鼓舞的结果。然而，尽管这些进展为患者及其家属提供了宝贵的希望，但关于胰腺肿瘤如何对靶向RAS疗法产生反应，以及未来的治疗策略如何实现更持久的获益，仍存在诸多重要问题。

Through a first-of-its-kind correlative research study launched in 2024, researchers in the original Conquering KRAS in Pancreatic Cancer TeamLab have already assembled an unprecedented collection of patient tumor and blood samples that may help answer those questions..

通过在2024年启动的一项首创性关联研究，原“攻克胰腺癌中的KRAS”TeamLab的研究人员已经收集了一批前所未有的患者肿瘤和血液样本，这可能有助于回答这些问题。

Building on years of progress, the new initiative will support this multi-disciplinary team of scientists and clinicians from six world-class cancer research institutions including Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT's Koch Institute for Integrative Cancer Research, The University of Texas MD Anderson Cancer Center, and NYU Langone Health Perlmutter Cancer Center, to tackle these challenges through an integrated program of translational science and clinical research..

在多年进展的基础上，新举措将支持来自六家世界级癌症研究机构的科学家和临床医生组成的多学科团队，这些机构包括丹娜—法伯癌症研究所、约翰斯·霍普金斯大学西德尼·金梅尔综合癌症中心、纪念斯隆-凯特琳癌症中心、麻省理工学院科赫整合癌症研究所、德克萨斯大学MD安德森癌症中心以及纽约大学朗格尼健康珀尔穆特癌症中心，通过转化科学与临床研究的整合项目来应对这些挑战。

'

'

Recent advances in RAS-targeted therapies have opened a new chapter in pancreatic cancer research'

靶向RAS治疗的最新进展开启了胰腺癌研究的新篇章

said Tyler Jacks, PhD, president of Break

Break总裁泰勒·杰克斯博士表示

Through

通过

Cancer and renowned pancreatic cancer researcher. '

癌症及著名的胰腺癌研究者。

This initiative is focused on what comes next – understanding how these therapies work in patients, the nature of primary and acquired resistance, and how we can develop treatment strategies that build upon the improvements of RAS-directed therapy alone.'

该倡议重点关注后续步骤——了解这些疗法在患者体内的作用机制、原发性和获得性耐药的性质，以及我们如何制定治疗策略，在单纯RAS靶向疗法改善效果的基础上进一步优化。

The new funding will support two complementary efforts.

新资金将支持两项相辅相成的工作。

First, researchers will continue and build on the research emerging from the first-of-its-kind clinical correlative study launched in 2024 through the Conquering KRAS in Pancreatic Cancer TeamLab which collected tumor and blood samples before, during, and after treatment with Revolution Medicine's daraxonrasib – an investigational novel multi-selective RAS(ON) inhibitor that recently made headlines following phase 3 trial results in patients with previously treated metastatic pancreatic cancer.

首先，研究人员将继续并拓展2024年启动的“胰腺癌KRAS攻关TeamLab”所开展的首创性临床相关性研究。该研究收集了患者在使用Revolution Medicine公司研发的daraxonrasib（一种在研的新型多重选择性RAS(ON)抑制剂）治疗前、治疗期间和治疗后的肿瘤和血液样本。Daraxonrasib最近在既往接受过治疗的转移性胰腺癌患者的III期临床试验结果公布后引起了广泛关注。

Researchers now have the unprecedented opportunity to analyze these samples and create one of the most comprehensive pictures to date of how pancreatic cancers respond and adapt to RAS-directed therapy. Insights from this work will help identify biomarkers of response, uncover mechanisms of resistance and adaptation, and inform combination therapy strategies..

研究人员现在拥有前所未有的机会来分析这些样本，并构建迄今为止关于胰腺癌对RAS靶向治疗的反应和适应机制的最全面图景之一。这项工作的见解将有助于识别治疗反应的生物标志物，揭示耐药性和适应性机制，并为联合治疗策略提供依据。

Second, researchers will establish a clinical study to evaluate next-generation treatment strategies informed by those discoveries. The TeamLab will explore combination therapies designed to enhance the benefit of KRAS-directed treatments, bringing together expertise in cancer biology, immunology, computational science, and patient care..

其次，研究人员将开展一项临床研究，以评估基于这些发现的下一代治疗策略。TeamLab 将探索旨在增强 KRAS 靶向治疗疗效的联合疗法，汇聚癌症生物学、免疫学、计算科学和患者护理领域的专业知识。

The effort builds upon the unique model of radical collaboration that defines Break

这一努力建立在定义 Break 的独特激进协作模式之上

Through

通过

Cancer, connecting researchers across leading cancer centers to share data, expertise, technologies, and patient insights in real-time. This approach is synergistic with Lustgarten's impact-driven research strategy, fueling bold science that deepens our understanding of pancreatic cancer and improves treatment outcomes..

癌症领域，连接各大顶尖癌症中心的研究人员，实时共享数据、专业知识、技术和患者洞察。这种方法与Lustgarten基金会以影响力为导向的研究战略相辅相成，推动大胆的科学探索，深化我们对胰腺癌的理解并改善治疗结果。

'

'

Pancreatic cancer research is entering a new era of possibility, and we must invest in the kind of collaborative science that transforms promising advances into meaningful progress for patients

胰腺癌研究正进入一个充满可能性的新时代，我们必须投资于那种能够将有望取得的进展转化为对患者具有实际意义的进步的协作性科学研究。

,' said Linda Tantawi, CEO of the Lustgarten Foundation. '

“，”Lustgarten基金会首席执行官琳达·坦塔维说，“

We are incredibly excited to support the next phase of the Conquering KRAS for Patients with Pancreatic Cancer TeamLab, uniting leading experts across institutions and disciplines to build on the momentum of recent discoveries. By accelerating collaboration and innovation, this initiative will answer critical questions, unlock new opportunities, and drive breakthroughs that shape the future of pancreatic cancer treatment..

我们非常激动地支持“征服胰腺癌患者KRAS突变”TeamLab的下一阶段工作，汇聚来自不同机构和学科的顶尖专家，延续近期发现的势头。通过加速合作与创新，这一举措将解答关键问题，开启新机遇，并推动突破，塑造胰腺癌治疗的未来。

'

'

The initiative reflects a shared commitment by Break

该倡议体现了Break的共同承诺

Through

通过

Cancer, the Lustgarten Foundation, and the Cinelli Family Foundation to accelerate progress against pancreatic cancer by investing in collaborative science capable of moving discoveries from the laboratory to patients more quickly.

癌症研究、Lustgarten 基金会以及 Cinelli 家族基金会，通过投资能够将发现从实验室更快转化为患者治疗的协作科学，以加速在胰腺癌防治方面的进展。

As RAS-directed therapies continue to advance, researchers believe the greatest opportunity may lie not in any single treatment, but in understanding how to deploy these therapies in combinations with other approaches to achieve lasting benefit.

随着RAS靶向治疗的不断进展，研究人员认为，最大的机遇可能不在于任何单一疗法，而在于理解如何将这些疗法与其他方法联合应用，以实现持久的疗效。

About Break

关于 Break

Through

通过

Cancer

癌症

Founded in 2021, Break

Break 成立于 2021 年

Through

通过

Cancer empowers outstanding researchers and physicians to both intercept and find cures for several of the deadliest cancers by stimulating radical collaboration among outstanding cancer research institutions, including its founding partners: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT's Koch Institute for Integrative Cancer Research, and The University of Texas MD Anderson Cancer Center..

癌症项目通过促进顶尖癌症研究机构之间的深度协作，赋能杰出的研究人员和医生，以拦截并治愈多种最致命的癌症。其创始合作伙伴包括：丹娜—法伯癌症研究所、约翰斯·霍普金斯大学西德尼·金梅尔综合癌症中心、纪念斯隆-凯特琳癌症中心、麻省理工学院科赫整合癌症研究所，以及德克萨斯大学安德森癌症中心。

The Foundation is supported by a Board of Directors from the five partner institutions and a Scientific Advisory Board of U.S. cancer experts. The Foundation was launched with an extraordinary challenge pledge of $250 million from Mr. and Mrs. William H. Goodwin, Jr. and their family, and the estate of William Hunter Goodwin III..

本基金会由来自五家合作机构的董事会以及一个由美国癌症专家组成的科学顾问委员会提供支持。基金会启动时，获得了小威廉·H·古德温夫妇及其家人，以及威廉·亨特·古德温三世遗产提供的2.5亿美元特别挑战承诺捐赠。

For further information, please visit the Foundation's website at

欲了解更多信息，请访问基金会的网站：

www.breakthroughcancer.org

www.breakthroughcancer.org

.

。

About The Lustgarten Foundation

关于拉斯特加滕基金会

The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer research, driving the pursuit of bold and innovative science toward earlier detection and better treatments, and transforming pancreatic cancer into a curable disease.

拉斯特加滕基金会是全球最大的胰腺癌研究私人资助机构，致力于资助顶尖的胰腺癌研究，推动大胆创新的科学研究以实现更早检测和更优治疗，并将胰腺癌转变为一种可治愈的疾病。

The Foundation funds research where creative risks yield high rewards to accelerate and expand life-saving treatment options. We believe time is everything to patients and their families, and that community is power. Lustgarten programs and events provide people affected by pancreatic cancer a voice and a place to create hope, together.

本基金会资助那些通过承担创造性风险而获得高回报的研究，以加速并拓展挽救生命的治疗选择。我们坚信，对于患者及其家人而言，时间至关重要，而社群则蕴含着力量。Lustgarten 的项目与活动为受胰腺癌影响的人们提供发声的平台和共同孕育希望的家园。

For more information about the Lustgarten Foundation, visit .

欲了解有关拉斯特加滕基金会的更多信息，请访问。

lustgarten.org

lustgarten.org

and follow us on

并在以下平台关注我们

Facebook

脸书

,

，

Instagram

Instagram

,

，

Bluesky

蓝天

,

，

LinkedIn

领英

, and

，和

YouTube

YouTube

.

。

About The Cinelli Family Foundation

关于奇内利家族基金会

The Cinelli Family Foundation (CFF) was established in 2021 to honor the dreams of Al and Sharon Cinelli. Inspired by the transformative power of education and shaped by cancers that impacted the Cinelli family, the Foundation invests in two areas where progress is both urgent and possible: accelerating breakthroughs in blood, breast, and pancreatic cancer prevention and treatment, and supporting education research, innovative programs, and technologies to help reimagine educational ecosystems and radically improve learning outcomes.

奇内利家族基金会（CFF）成立于2021年，旨在实现阿尔和莎伦·奇内利的梦想。受教育的变革力量以及影响奇内利家族的癌症经历的启发，该基金会致力于在两个既紧迫又充满进展可能的领域进行投资：一是加速血液癌、乳腺癌和胰腺癌预防与治疗方面的突破；二是支持教育研究、创新项目和技术，以帮助重构教育生态系统，从根本上改善学习成果。

Based in Lawrence, Kansas, CFF is a national funder driven by the belief that science and learning are among the most powerful forces for human progress..

CFF 总部位于堪萨斯州劳伦斯，是一家全国性资助机构，秉持科学与学习是推动人类进步最强大力量之一的信念。

For more information, visit

更多信息，请访问

www.cinellifamilyfoundation.org

www.cinellifamilyfoundation.org

.

。

Media Contact:

媒体联系人：

Soracha Ward

索拉查区

[email protected]

[email protected]

SOURCE Break Through Cancer

来源：突破癌症

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示